Searchable abstracts of presentations at key conferences in endocrinology

ea0089o12 | Other | NANETS2022

An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?

A Trikalinos Nikolaos , Hammill Chet , Liu Jingxia , Navale Pooja , Winter Kyle , Chatterjee Deyali , Iravani Amir , Amin Manik , Itani Malak

Background: Subspecialty tumor boards (TB) are uncommon and their benefit has not been clearly demonstrated for patients and providers alike. We tried to determine the decision patterns of a newly minted neuroendocrine neoplasm (NEN) tumor board (TB) and the factors behind those.Methods: We retrospectively reviewed all NEN TB recommendations from 07/2018 to 12/2021 and recorded patient characteristics, TB outcomes and associations between them.<p cla...

ea0047oc31 | Spotlight on Prostate Cancer | Theranostics2016

First in-man study of 68Ga-THP-PSMA PET in patients with primary prostate cancer: initial results

Hofman Michael S. , Eu Peter , Mitchell Catherine , Blower Phil , Iravani Amir , Murphy Declan , Young Jennifer , Hicks Rod J. , Mullen Gregory E.

Ga-68 labelled urea-based inhibitors of the prostate specific membrane antigen (PSMA), such as 68Ga-HBED-PSMA-11, are promising peptides for targeting prostate cancer. The tris(hydroxypyridinone) (THP) ligand rapidly complexes 68Ga3+ at room temperature, at very low concentration and over a wide pH range, making it possible for the direct elution from a 68Ge/68Ga generator into a cold radiopharmaceutical kit in one step wi...